视觉与半定量联合评估提升中期FDG PET对弥漫大B细胞淋巴瘤的预后预测
该研究在145例新诊断弥漫大B细胞淋巴瘤患者中,比较了中期FDG PET(PET-2)的Deauville视觉5分法(5-PS)与SUV变化率(ΔSUV)半定量法的预测价值。两种方法单独评估时iPET阴性组与阳性组无进展生存期均有显著差异(P < 0.001);5-PS联合ΔSUV < 48.9%的联合分类阴性预测值和阳性预测值分别为89%和100%。
要点
- 5-PS与ΔSUV单独评估均可显著区分iPET阴性与阳性组的无进展生存期(P < 0.001)。
- ΔSUV 48.9%截断值特异性达100%,敏感性最高为24%。
- 5-PS联合ΔSUV < 48.9%分类的阴性预测值89%、阳性预测值100%。
核心结论
- 中期FDG PET无论采用视觉5-PS还是半定量ΔSUV评估,在弥漫大B细胞淋巴瘤中均具有良好预后价值。
- ΔSUV最有效截断值为48.9%,与5-PS联合时阳性PET-2结果高度预测治疗失败。
研究设计与样本
- 共纳入145例新诊断弥漫大B细胞淋巴瘤患者,治疗前及PET-2均行FDG PET评估。
- PET-2分别按Deauville视觉5分法(5-PS)和SUV变化率(ΔSUV)百分比分类,并采用受试者工作特征分析比较两种方法预测无进展生存期的准确性。
- 按各方法单独及联合分类计算iPET阳性与阴性组的生存估计并比较。
主要发现
- 5-PS与ΔSUV评估均显示iPET阴性组与阳性组无进展生存期差异显著(P < 0.001)。
- 5-PS以Deauville评分4-5定义为阳性时,阴性预测值89%、阳性预测值59%。
- 采用既往报道的66% ΔSUV截断值时,阴性预测值80%、阳性预测值76%。
- ΔSUV 48.9%截断值(本文首次报道)特异性100%、敏感性最高为24%。
- 5-PS与ΔSUV < 48.9%对PET-2分类一致者占70%(102/145),联合分类阴性预测值89%、阳性预测值100%,所有iPET阳性患者均未达到或维持缓解。
关键数值与推荐
- 5-PS阳性定义为Deauville评分4-5分,阴性预测值89%、阳性预测值59%。
- ΔSUV 66%截断值:阴性预测值80%、阳性预测值76%。
- ΔSUV 48.9%截断值:特异性100%、敏感性24%。
- 5-PS联合ΔSUV < 48.9%分类:阴性预测值89%、阳性预测值100%。
临床怎么用
- 中期FDG PET可采用Deauville视觉5-PS或ΔSUV半定量评估进行早期疗效判断。
- 5-PS联合ΔSUV < 48.9%分类可提高阳性预测值,阳性PET-2结果高度提示治疗失败。
局限性
- ΔSUV 48.9%截断值敏感性仅24%,可能漏诊部分治疗失败患者。
- 5-PS与ΔSUV分类仅在70%(102/145)患者中一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to assess the predictive and prognostic value of interim FDG PET (iPET) in evaluating early response to immunochemotherapy after 2 cycles (PET-2) in diffuse large B-cell lymphoma (DLBCL) by applying 2 different methods of interpretation: the Deauville visual 5-point scale (5-PS) and a change in SUV (ΔSUV) by semiquantitative evaluation. Methods: In total, 145 patients with newly diagnosed DLBCL underwent pretreatment PET and PET-2 assessment. PET-2 was classified according to both 5-PS and percentage ΔSUV. Receiver-operating-characteristic analysis was performed to compare the accuracy of the 2 methods for predicting progression-free survival. Survival estimates, based on each method separately and combined, were calculated for iPET-positive (iPET+) and iPET-negative (iPET-) groups and compared. Results: Both with 5-PS and with ΔSUV-based evaluations, significant differences were found between the progression-free survival of iPET- and iPET+ patient groups (P < 0.001). Visually, the best negative predictive value (NPV) and positive predictive value (PPV) occurred when iPET was defined as positive if the Deauville score was 4-5 (89% and 59%, respectively). Using the 66% ΔSUV cutoff reported previously, NPV and PPV were 80% and 76%, respectively. ΔSUV at the 48.9% cutoff, reported for the first time here, produced 100% specificity along with the highest sensitivity (24%). The 5-PS and a semiquantitative ΔSUV of less than 48.9% for each PET-2 gave the same PET-2 classification (positive or negative) in 70% (102/145) of all patients. This combined classification delivered NPV and PPV of 89% and 100%, respectively, and all iPET+ patients failed to achieve or remain in remission. Conclusion: In this large consistently treated and assessed series of DLBCL patients, iPET had good prognostic value interpreted either visually or semiquantitatively. We determined that the most effective ΔSUV cutoff was 48.9% and that when combined with 5-PS assessment, a positive PET-2 result was highly predictive of treatment failure.
引用
- Györke T, Carr R, Cerci JJ, et al. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment 18F-FDG PET in Diffuse Large B-Cell Lymphoma. J Nucl Med. 2019. PMID: 31757842. doi:10.2967/jnumed.119.231621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。